化疗联合免疫疗法治疗胃癌的临床疗效分析

Clinical Efficacy of Chemotherapy Combined with Immunotherapy in the Treatment of Gastric Cancer

目的探讨化疗联合免疫疗法治疗胃癌的临床疗效。方法便利选取枣庄市立医院2020年1月—2023年8月收治的86例胃癌患者作为研究对象,根据随机数表法分为两组,各43例。对照组使用化疗治疗,观察组使用化疗联合免疫疗法治疗。对比两组的近期疗效、不良反应发生率、淋巴细胞计数、生存指标。结果观察组治疗有效率为62.79%、临床控制率为86.05%,明显高于对照组的39.53%、65.12%,差异有统计学意义(χ^(2)=4.654、5.103,P均<0.05)。观察组不良反应发生率与对照组相比,差异无统计学意义(P>0.05)。观察组治疗后淋巴细胞计数高于对照组,差异有统计学意义(P<0.05)。观察组生存时间长于对照组,1年生存率高于对照组,差异有统计学意义(P均<0.05)。结论化疗联合免疫疗法治疗胃癌的临床疗效显著,能有效改善免疫抑制,减轻化疗所致免疫损伤,增强对肿瘤的抑制力。

Objective To explore the clinical efficacy analysis of chemotherapy combined with immunotherapy in the treatment of gastric cancer.Methods A total of 86 patients with gastric cancer admitted to Zaozhuang Municipal Hospital from January 2020 to August 2023 were conveniently selected as the study objects and divided into two groups according to random number table method,with 43 cases in each group.The control group was treated with chemotherapy,and the observation group was treated with chemotherapy combined with immunotherapy.The short-term efficacy,the incidence of adverse reactions,lymphocyte counts and survival indexes of the two groups were compared.Results The treatment effective rate and clinical control rate of the observation group were 62.79%and 86.05%,which were significantly higher than those of the control group 39.53%and 65.12%,and the differences were statistically significant(χ^(2)=4.654,5.103,both P<0.05).The incidence of adverse reactions in the observation group compared to that in the control group,and the difference was not statistically significant(P>0.05).The lymphocyte count in the observation group was higher than that in the control group after treatment,and the difference was statistically significant(P<0.05).The survival time of the observation group was longer than that of the control group,and the 1-year survival rate was higher than that of the control group,and the differences were statistically significant(both P<0.05).Conclusion The clinical efficacy of chemotherapy combined with immunotherapy in the treatment of gastric cancer is remarkable,which can effectively improve the immunosuppression,reduce the immune injury caused by chemotherapy,and enhance the inhibitory power against tumor.